Onconetix (ONCO) Registration Filing summary

Company overview and business model

• Commercial-stage biotechnology company focused on men's health and oncology, with a primary asset in Proclarix, a CE-marked in vitro diagnostic test for prostate cancer, and a paused/abandoned commercialization of ENTADFI, a BPH treatment pill.

• Proclarix is approved in the EU and expected to generate revenue by 2025; U.S. commercialization is through a license with Labcorp.

• The company relies on third parties for manufacturing and distribution, with no internal manufacturing capabilities.

• Since inception, the company has focused on R&D, acquisitions, and building a portfolio in therapeutics, diagnostics, and clinician services for men's health and oncology.

Financial performance and metrics

• As of June 30, 2024, working capital deficit was approximately $18.6 million and accumulated deficit was about $82.2 million.

• Cash balance as of October 30, 2024, was approximately $595,000, with $5 million of debt due in each of March and June 2025.

• The company has incurred net losses since inception and expects to continue to do so for the foreseeable future.

• Current liabilities as of June 30, 2024, were approximately $20.6 million.

Use of proceeds and capital allocation

• May receive up to $25 million in gross proceeds from Keystone under the ELOC Purchase Agreement, but actual proceeds may be less depending on share price and volume sold.

• 30% of gross proceeds from ELOC sales must be used to redeem Series C Preferred Stock; 20% of net proceeds must be paid to Veru to reduce outstanding obligations.

• Remaining proceeds will be used for general corporate and working capital purposes at the Board's discretion.